



AALBORG UNIVERSITY
DENMARK

Aalborg Universitet

Core outcome domains for lichen sclerosis

a CORALS initiative consensus statement

Simpson, Rosalind C.; Kirtschig, Gudula; Selk, Amanda; von Seitzberg, Suzanne; Vittrup, Gitte; Bissonnette, Ione; Kottner, Jan; Lanthier, Jaclyn; Stanton, Chris; Foster, David; Promm, Martin; Augenti, Angelo; Lauretti, Stefano; Thomas, Kim S.; Core Outcomes for Research in Lichen Sclerosus (CORALS) initiative steering group

Published in:

British Journal of Dermatology

DOI (link to publication from Publisher):

[10.1093/bjd/ljac145](https://doi.org/10.1093/bjd/ljac145)

Creative Commons License

CC BY 4.0

Publication date:

2023

Document Version

Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Simpson, R. C., Kirtschig, G., Selk, A., von Seitzberg, S., Vittrup, G., Bissonnette, I., Kottner, J., Lanthier, J., Stanton, C., Foster, D., Promm, M., Augenti, A., Lauretti, S., Thomas, K. S., & Core Outcomes for Research in Lichen Sclerosus (CORALS) initiative steering group (2023). Core outcome domains for lichen sclerosis: a CORALS initiative consensus statement. *British Journal of Dermatology*, 188(5), 628-635. [ljac145]. <https://doi.org/10.1093/bjd/ljac145>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

1 Core outcome domains for lichen sclerosis: a CORALS initiative consensus statement

2
3 **Running Head:** CORALS Core Domains

4
5
6 Rosalind C. Simpson,¹ Gudula Kirtschig,² Amanda Selk,³ Suzanne von Seitzberg,⁴ Gitte Vittrup,⁵ Lone
7 Bissonnette,⁶ Jan Kottner,⁷ Jaclyn Lanthier,⁸ Chris Stanton,⁹ David Foster,¹⁰ Martin Promm,¹¹ Angelo
8 Augenti,¹² Stefano Lauretti,¹² Kim S. Thomas¹ and The Core Outcomes for Research in Lichen Sclerosis
9 (CORALS) initiative steering group.

10
11 ¹ Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK

12 ² Medbase Health Centre Frauenfeld, Switzerland

13 ³ University of Toronto, Toronto, Canada

14 ⁴ The Danish Lichen Sclerosis Association, Denmark

15 ⁵ North Denmark Regional Hospital, Hjoerring, Denmark

16 ⁶ CNM, MSN, co-author VulvovaginalDisorders.org, Massachusetts, USA

17 ⁷ Charité-Universitätsmedizin Berlin, Germany

18 ⁸ Patient Representative & The Lost Labia Chronicles

19 ⁹ Patient Representative

20 ¹⁰ University of Rochester, New York, USA

21 ¹¹ Department of Pediatric Urology and Regensburg University, Germany

22 ¹² S. Caterina della Rosa Genital Surgery, Rome, Italy

23
24 **Corresponding author:** Rosalind C. Simpson

25 **Email:** Rosalind.simpson@nottingham.ac.uk

26 27 **Abstract**

28
29 **Background:** Lichen sclerosis (LS) is a chronic inflammatory condition mainly affecting genital skin. It
30 causes distressing symptoms that impact daily quality of life (QoL). It causes progressive anatomical
31 changes and a potential risk of cancer. Published randomised controlled trials are of varying
32 methodological quality and difficult to combine in meta-analyses. This is partly due to lack of agreed
33 outcome measures to assess treatment response. Identification of core outcome sets (COSs), which
34 standardise key outcomes to be measured in all future trials, is a solution to this problem.

35 **Objectives:** To obtain international agreement on which outcome domains should be measured in
36 interventional trials of genital LS.

37 **Methods:** Recommended best practice for COS domain development was followed: 1) Identification of
38 potential outcome domains: a long-list was generated through up-to-date LS literature search, including
39 information collected during the LS Priority Setting Partnership. 2) Provisional agreement of outcome
40 domains: A 3-stage multi-stakeholder international electronic-Delphi consensus study; 3) Final
41 agreement of outcome domains: Online consensus meeting with international stakeholders including
42 anonymised voting.

1 **Results:** In total, 123 participants (77 patients, 44 health professionals, 2 researchers) from 20 countries
2 completed 3 rounds of the electronic-Delphi study. 11 outcome domains were rated as 'critical' and
3 were discussed at the online consensus meetings. The first set of consensus meetings involved 42
4 participants from 13 countries. Consensus was met for 'symptoms' (100% agreed) and 'quality of life-LS
5 specific' (92% agreed). After set two of meetings, involving 29 participants from 12 countries, 'Clinical
6 (visible) signs' also met consensus (97% agreed).

7 **Conclusions:** The international community have agreed upon 3 key outcome domains to measure in all
8 future LS clinical trials. We recommend that trialists and systematic reviewers incorporate these
9 domains into study protocols with immediate effect. CORALS will now work with stakeholders to select
10 an outcome measurement instrument per prioritised core domain.

11 Introduction

12
13
14 Core outcome sets (COS) aim to reduce research waste by ensuring that outcomes measured in
15 randomised controlled trials (RCTs) of a specific condition can be compared and combined in meta-
16 analyses to provide a stronger treatment evidence base.¹ COSs ensure that all trials of a particular
17 condition measure the same key outcomes so that they are comparable. However, it does not prevent
18 researchers from measuring other additional outcomes relevant to their specific study.² There is an
19 international movement to promote COS, supported by initiatives such as COMET (Core Outcome
20 Measures for Effectiveness Trials)³, CROWN (Core Outcomes for Women's and Neonatal Health)⁴ and
21 C3 (The CHORD COUSIN Collaboration).⁵ Leading peer reviewed journals support implementation of COS
22 by ensuring that if one exists, the core outcomes are reported in published research.⁶

23
24 There is considerable variation in outcome measurement for vulval disease.⁷ Lichen sclerosus (LS) is an
25 important, albeit under recognised condition which affects at least 1% of women of all ages⁸⁻¹⁰ but also
26 affects children and men, and usually runs a chronic course. An estimated 3-5% of cases develop
27 malignancy.^{11,12} LS has a significant impact on quality of life (QoL) and affects psychosocial and sexual
28 wellbeing¹³⁻¹⁵ Lack of validated outcome measures and heterogeneity in published RCTs limits high
29 quality evidence to guide clinical practice.¹⁶ Agreement regarding outcomes has been identified as a
30 need in an international priority setting partnership.¹⁷ Due to an increase of trials testing new
31 treatments for LS, such as laser, platelet rich plasma and alternative topical treatments, which may be
32 costly and/or have potential serious side effects, the need to standardise outcome measurement in LS is
33 paramount.

34
35 CORALS (Core Outcomes for Research in Lichen Sclerosus) is an initiative led by a multi-stakeholder
36 steering group which aims to create, via international consensus, a COS for future genital LS trials. COS
37 development takes place in two stages: 1. Agreement of core outcome domains and 2. Agreement of
38 core outcome measurement instruments.

39
40 The aim of this stage of CORALS was to obtain international agreement on which *domains* should be
41 measured as a minimum requirement in interventional trials of genital LS.

42 Methods

43
44
45 A multidisciplinary steering group with representation from dermatology, gynaecology, nursing, urology,
46 patients (male and female) and methodologists, with independent oversight from a C3 representative,
47 was formed to drive this initiative forward. Ethical approval was obtained from the Faculty of Medicine

1 and Health Sciences Research Ethics Committee of the University of Nottingham (Ref: 376-1908). Online
2 consent was obtained for participation in the electronic-Delphi (e-Delphi) survey.

3
4 The protocol was developed in line with CS-COUSIN (Cochrane Skin Core Outcomes Initiative, now
5 known as C3) guidance and followed Core Outcome Set-STAndards for Development (COS-STAD)
6 recommendations¹⁸ and accepted methodology.¹⁹ It was prospectively made publicly available.²⁰ The
7 intention to develop a COS in LS was also registered on the COMET, CROWN and C3 websites. The scope
8 of this COS was all patients with LS, all treatments, and all settings.

9
10
11 Development of domains took a three-stage process:

- 12 1. Identification of possible domains using key documents in the literature
- 13 2. Provisional agreement of the most important domains via a 3-stage e-Delphi consensus study
- 14 3. Final agreement of domains: international virtual consensus meetings

15 16 17 *Identification of potential domains*

18
19 A long list of possible outcome domains was identified through randomised controlled trials included in
20 key guideline and systematic review documents^{10,16,21} as well as qualitative published studies.²²⁻²⁴

21
22 Domains were extracted from these documents independently by three steering group members (RS,
23 GK, AS). These were then reviewed by the whole Steering Group and any domains perceived to be
24 missing were added. Similar domains were grouped together and summarized to create a list of
25 meaningful concepts and definitions, based upon agreed taxonomy.²⁵ Patient representatives advised
26 on wording of domains to be understandable by members of the public.

27 28 *Provisional agreement of the most important domains*

29
30 The long list of domains was entered into a three-stage e-Delphi consensus study using 'Delphi Manager'
31 software from the COMET group.²⁶ Although the main e-Delphi survey was in English, to increase
32 accessibility, participant information sheets and the survey welcome page were available into nine
33 different languages. Support for participants with translation of the survey was offered although this
34 was not taken up.

35
36 Stakeholders included health care professionals, patients, patient representatives/carers, researchers
37 and systematic reviewers in the field of LS, industry representatives and journal editors. Stakeholders
38 were identified through the International Society for the Study of Vulvovaginal Disease (ISSVD), the
39 British Society for the Study of Vulval Disease (BSSVD), the Australian and New Zealand Vulvovaginal
40 Society (ANZVS), European College for the Study of Vulvar Disease (ECSVD), the Indian Chapter of the
41 ISSVD and the North American Chapter of the ISSVD. Editors of journals signed up to the CROWN and
42 COMET initiatives were invited. Patients were identified through international LS patient support
43 groups. Invitations were sent via a range of methods including advertisements on social media,
44 mailshots to members of the relevant societies and direct email invitations to people recognised as key
45 figures in the field of LS. Those stakeholders who expressed interest via an online form were
46 subsequently provided with the survey links once available.

47

1 Delphi round 1 asked participants to score the importance of each outcome domain on a 9-point Likert
2 scale (1-3=not important, 4-6=important but not critical, 7-9=critical) and an 'unable to score' option.
3 Each domain had a plain English description of its definition available by 'hovering' over the domain.
4 Participants were allowed to provide feedback on individual domains and suggest additional domains if
5 they felt any were missing. Feedback was collated and discussed with the Steering Group with plans to
6 reword domains if necessary. Additional items were categorised and assessed against the long list of
7 domains to check whether any were missing. Outcome domains that were missed were added for voting
8 upon in the second round of the e-Delphi survey.
9

10 Definition of consensus was determined *a priori*. Criteria for a domain to be considered as part of the
11 COS was if at least 70% of participants scored an outcome as 'critical' with 15% or less of participants
12 voting as not important'. Analysis was undertaken by downloading Delphi-manager scores to a
13 Microsoft Excel spreadsheet and calculating for each of the domains the percentage of respondents who
14 voted 1-3 (not important), 4-6 (important but not critical), 7-9 (critical).
15

16 Domains that did not meet consensus as 'critical' after two rounds were removed. Subsequently, round
17 3 used 'Survey-monkey'²⁷ to present the outcome domains that had reached consensus as being 'critical'
18 and asked participants to rank them in terms of their importance (1= most important, 11=least
19 important). Items were presented to participants in a randomised order to minimise bias when ranking.
20 Survey-monkey automated analysis was used to calculate the average ranking for each answer choice to
21 determine which answer choice was most preferred overall i.e., the answer choice with the largest
22 average ranking represents the most preferred choice. We calculated ranking for each stakeholder
23 group, as well as overall rankings.
24

25 Reminder emails were sent to participants at key stages of the process to ensure maximum return of the
26 e-Delphi survey questionnaire.
27

28 *International consensus meetings*

29 The aim of the consensus meeting was to agree on core domains for the future LS COS. As a result of the
30 COVID-19 pandemic, it was not felt appropriate to hold 'in-person' consensus meetings as described
31 from previous published COSs. Therefore, using 'Microsoft Teams', we held two sets of virtual consensus
32 meetings. Each meeting set had two dates at different times where the content and processes were
33 repeated. This provided the opportunity for stakeholders from different time zones to participate. To
34 encourage as wide international engagement as possible, the meetings were opened to CORALS' wider
35 contact network as well as those who participated in the e-Delphi surveys. Pre-meeting information was
36 circulated detailing the process to date and results from the e-Delphi surveys. Tasks were set to
37 encourage participants to consider in advance which domains meant most to them.
38

39 The sessions comprised a mixture of presentations, whole group discussion and smaller moderated
40 breakout groups. Moderators were instructed to remain impartial and facilitate discussion but not voice
41 their opinion. There was a moderator guide (Appendix S1) to support standardisation of the breakout
42 groups.
43

44 In the whole group session, outcome domains were presented in detail. Then to prioritise domains
45 down to the core minimum, the smaller groups were asked to determine their 'top 3' domains. Breakout
46 group results were presented to the main group and after further discussion participants were asked to
47 vote anonymously, using Microsoft Forms, for each of the domains by asking the question '*should the*
48 *domain be in the final core outcome set? Yes/no/not sure*'. A backup questionnaire was prepared to

1 send immediately after the meeting had ended to participants who identified as unable to vote during
2 the live sessions. To avoid bias, results from the consensus meetings were not shown to participants
3 until both meetings were complete and those who couldn't vote live had been given the opportunity to
4 complete the questionnaire.

5
6 Definition of consensus was if 70% or more agreed, then the domain would be in the COS. If more than
7 30% disagreed, the domain was not added into the COS. In the situation where <70% agreed, but less
8 than 30% disagreed, the domain was considered as "provisionally in the COS", pending further
9 discussion and voting. Any dissenting views were discussed with the whole group to allow others to
10 consider and gather wider opinion.

11 12 13 **Results**

14
15 Apart from the decision to conduct two online consensus meetings instead of face-to-face meetings,
16 there were no deviations from the protocol.

17
18 Initial literature review identified a list of 11 broad outcome domains (Table 1). Demographics of
19 participants in the e-Delphi consensus process and the virtual consensus meetings are in table 2.

20 21 *Delphi consensus survey*

22 During round 1 (April 26th 2021 – June 4th 2021), 64 additional items were suggested by participants to
23 include. Of these 46 were not outcomes (treatments n=14, LS causes n=8, disease course n=7, LS clinical
24 follow-up n=4, LS education n=4, LS treatment regimen n=2, other n=7). The 18 suggested outcomes
25 were categorised into 3 overarching domains (adverse events, emotional/psychological impact,
26 treatment acceptability). Therefore, in Round 2 (8th-31st August 2021), participants voted on 14
27 outcomes. Of these 11 were voted as 'critical' by at least one stakeholder group (table 3) and went
28 through to round 3 for ranking. The three outcome domains removed were impact on important
29 relationships, histological changes and societal/resource use.

30
31 Following the ranking round, the top three domains for health care professionals'/researchers' (n=45)
32 were: 1. Symptoms; 2. Control of disease; 3. Development of cancer. The top three domains for
33 patients/patient representatives' (n=77) were: 1. Control of disease; 2. Symptoms; 3. Sexual functioning.
34 Combined ranking results for all stakeholder groups are shown in Figure 1.

35 36 *Virtual consensus meetings*

37 Meetings held on January 26th and 28th 2022 had 42 participants (21 health professionals, 15
38 patients/patient representatives, 6 researchers) from 12 different countries. Representation from all
39 stakeholder groups, including minority groups (men and representatives of children), was present. Due
40 to technical difficulties, not all participants voted despite the opportunity to do so during the meeting. A
41 follow-up questionnaire was available for those who couldn't vote in real-time. Overall, each of the
42 outcome domains received votes from at least 90% (38/42) of participants.

43
44 Of those who voted, 100% voted 'yes' for the '**symptoms**' domain to be in the COS. Overall, 92% (36/39)
45 voted for '**quality of life – LS specific**' to be in the final COS. '**Control of disease**' and '**clinical (visible)**
46 **signs**' were close to consensus (65% and 64% voted 'yes', respectively). A further meeting was arranged
47 for further discussion and voting of these latter two domains. The remaining seven outcome domains
48 were not voted into the final COS.

1
2 The second set of consensus meetings (May 25th and June 9th 2022) focused on ‘**control of disease**’ and
3 ‘**clinical (visible) signs**’ only. There were 29 participants overall (14 health care professionals, 9
4 patients/patient representatives, 6 researchers) from 12 countries. Discussion centred around the
5 definition of ‘control of disease’ and whether it represented a standalone outcome or incorporated
6 repeated measures of other markers of control (e.g., signs, symptoms, quality of life) over time. There
7 was also discussion about ‘clinical signs’ as being an objective measure as it is measured by the clinician
8 rather than being patient reported.
9

10 The domain ‘Clinical (visible) signs’ was voted to be included in the final COS (28/29, 97% votes),
11 whereas ‘control of disease’ did not receive sufficient votes to be included in the final COS (5/29, 17%
12 votes).
13

14 During the consensus meetings, the ‘development of cancer’ and ‘sexual function’ domains were also
15 discussed at length. It is acknowledged that whilst these are significantly important outcomes, they are
16 not relevant to all trials of genital LS in all people. For example, development of cancer is a rare and
17 long-term outcome. To include it as a core outcome, all LS trials would need to continue for sufficient
18 duration to identify cancer development. Sexual function is not relevant to children or adults who are
19 not sexually active and is likely to be captured when measuring quality of life.
20

21 22 **Discussion**

23
24 CORALS followed methodology in line with accepted best practice for COS development and as such,
25 used a robust and accepted process to obtain international consensus.¹⁹ After three rounds of e-Delphi
26 surveys and two online consensus meetings, there was international agreement for three core domains
27 to be included in all future LS clinical trials: Symptoms, Clinical (visible) signs and quality of life – LS
28 specific.
29

30 Using bespoke software to manage the e-Delphi consensus process was beneficial in tracking
31 participants and individualising communications to maximise participation. However, as Delphi manager
32 was unable to allow ranking, a separate software was needed for round 3. An attrition of 38%
33 participants was seen between e-Delphi round 1 and round 3. This is higher than experienced in other
34 similar COS projects which report between 9-20% dropout²⁸⁻³⁰ but lower than in a recently published
35 COS development project.³¹ The cause is likely to be multifactorial but is particularly attributable to
36 workplace and life pressures faced during the COVID 19 pandemic.
37

38 Face-to-face consensus meetings, as traditionally used for previously published COSs, were not feasible
39 due to challenges faced during and after the COVID-19 pandemic. Guidance issued through the COMET
40 initiative was consulted to support the smooth running of the meetings and give the greatest chance of
41 success.³² We found that engagement from international stakeholders across the four virtual meetings
42 was strong and potentially led to better attendance than an in-person event. Earlier meetings reported
43 for other COS groups had fewer participants overall despite the disease areas being more common.³³⁻³⁶
44

45 Preparing participant resources that were circulated two weeks in advance was beneficial in meeting
46 preparation. Test voting at the beginning of the meetings helped to identify technical issues that some
47 participants were experiencing and most of these could be resolved prior to the real voting. Having a

1 backup questionnaire to send out immediately to participants who couldn't vote live was also helpful to
2 maximise votes.

3
4 There was good geographical representation overall, but participants from the far East and Africa/India
5 were not represented. CORALS must work to engage participants from these locations in future. In the
6 e-Delphi surveys, there was also minimal representation from researchers and none from
7 histopathologists. This led to concern at the consensus meetings that the domain 'histological changes'
8 was voted out too early as a result. However, a greater number of researchers were present at the
9 virtual meetings and this concern was not shared. To agree that histological changes should be a core
10 outcome would mean that ALL clinical trials in LS would need to take serial biopsies, e.g. from the
11 genital site (vulva /penis), as part of their protocol. This is not practical to implement and would likely
12 limit uptake of the COS.

13
14 Representation of minority groups (male patients and representatives of children) was relatively low
15 during the e-Delphi surveys. A similar pattern of under-representation has been reported previously and
16 reasons cited are that males are less willing than women to engage with health-related surveys and that
17 LS is less common in children.¹⁷ The numbers of these groups were proportionately higher in the virtual
18 consensus meetings suggesting greater motivation to attend a meeting rather than enter a survey, or
19 that CORALS had succeeded in promoting the initiative more widely.

20
21 Challenges to consider moving forward with the next stages of this COS are whether the different
22 groups affected by LS - males, females, and children - can be kept together when identifying core
23 outcome measure instruments. A COS that is applicable to greater numbers of people is likely to
24 generate more powerful evidence longer-term than one that used for groups separately, however, it
25 may not be practicable or possible to agree on instruments that are applicable to all. For example,
26 capturing QoL in different age groups is challenging as instruments designed for adults are not tailored
27 for the needs of children. However, this has been overcome in other COS initiatives as certain QoL tools,
28 such as the dermatology life quality index (DLQI) has versions validated in different age groups.³⁷

29
30 CORALS has agreed upon a small number of core domains which we hope will encourage researchers to
31 adopt the final set more easily. Some COS groups have a larger number of domains – for example acne³⁸
32 (six core domains), capillary malformations³⁹ (11 core domains), but CORALS is similar to eczema³⁰ (four
33 core domains). There are similarities in the chosen domains to other initiatives; hidradenitis
34 suppurativa²⁹, eczema and acne have chosen general clinical signs, whereas vitiligo have specified
35 repigmentation as the important clinical sign to measure. Condition-specific QoL was agreed in HS and
36 eczema. 'Symptoms' were agreed upon for eczema but not for HS nor vitiligo.

37
38 The domains 'clinical signs' and 'symptoms' are broad and may possibly need further breaking down.
39 Further discussion on 'QoL-LS specific' is also needed to ascertain whether an overall genital QoL tool is
40 acceptable, as it would potentially have greater use across other genital disease COS in the long-term.
41 Other initiatives, such as the incontinence associated dermatitis group⁴⁰, have chosen domains that are
42 specific to the disease state. There is no published guidance on how broad or specific to be.

43
44 Although outcome measure instruments for LS are not identified as yet, we recommend that
45 implementation of the core domains should start with immediate effect. Trialists and researchers should
46 include these three domains in their protocols and systematic reviewers should report these domains in
47 their work.

48

1 The next steps are to generate international working groups for each of the domains. The groups will
2 identify existing outcome measurement instruments and evaluate the quality of evidence regarding
3 their measurement properties. These will then be discussed at further international consensus meetings
4 to form the final LS COS. CORALS should work to increase global participation, particularly from under-
5 represented geographical regions and minority groups.
6
7

8 **Acknowledgements**

9

10 We thank all participants of the Delphi consensus process and the consensus meetings for their time and
11 willingness to participate. We also acknowledge the support of the ISSVD and BSSVD in raising
12 awareness of the CORALS through their membership. Thank you to C3 for provision of methodological
13 support. Finally, thank you to our steering group patient representatives, both past and present, for
14 their continued valuable input.
15
16

17 **Funding:** This study was developed with support from the UK Dermatology Clinical Trials Network (UK
18 DCTN) via the 2018 'Themed Call' award. The UK DCTN is grateful to the British Association of
19 Dermatologists and the University of Nottingham for financial support of the Network.
20

21 **Conflicts of interest:** There are no conflicts of interest to declare from any members of the Steering
22 Group
23

24 **Data availability:** Data available on request.
25

26 **Ethics statement:** Not applicable
27
28
29

30 **What's already known about this topic?**

- 31 • Agreement of outcomes is an international priority area for lichen sclerosis research.
- 32 • Core outcome sets reduce research waste by ensuring that outcomes measured in randomised
33 controlled trials (of a specific condition) can be compared and combined in meta-analyses to
34 provide a stronger treatment evidence base.
- 35 • There is currently no core outcome set for genital lichen sclerosis trials.
36

37 **What does this study add?**

- 38 • CORALS provides international multi-stakeholder consensus on core outcome domains for
39 clinical trials in genital lichen sclerosis.
- 40 • The core domains are relevant to all people with genital lichen sclerosis – males, females, adults
41 and children.
- 42 • The three internationally agreed core domains are: Clinical (visible) signs, symptoms and quality
43 of life specific to lichen sclerosis.
44

45 **What are the clinical implications of this work?**

- 1 • Implementation of the core domains into the protocols of randomised controlled trials and
2 systematic reviews will ensure that outcomes of importance to both patients and health
3 professionals are measured in future lichen sclerosis research.

4References:

- 5
- 6 1. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to
7 consider. *Trials*. 2012 Aug 6;13:132. doi: 10.1186/1745-6215-13-132. PMID: 22867278; PMCID:
8 PMC3472231.
- 9 2. Clarke M. Standardising outcomes for clinical trials and systematic reviews. *Trials*. 2007 Nov 26;8:39.
10 doi: 10.1186/1745-6215-8-39. PMID: 18039365; PMCID: PMC2169261.
- 11 3. Core Outcome Measures in Effectiveness Trials (COMET) webpage: <http://www.comet-initiative.org/>.
12 Last accessed 14/10/2022
- 13 4. Molloy EJ, Gale C, Marsh M, et al. Developing core outcome set for women's, newborn, and child
14 health: the CROWN Initiative. *Pediatr Res*. 2018 Sep;84(3):316-317. doi: 10.1038/s41390-018-0041-9.
15 Epub 2018 May 3. PMID: 30013151.
- 16 5. The CHORD COUSIN Collaboration (C3) webpage <https://www.c3outcomes.org>. Last accessed
17 14/10/2022
- 18 6. Veysey EC, Ingram JR, Apfelbacher CJ, Drucker AM. Core outcome set implementation supported by
19 the BJD. *Br J Dermatol*. 2021 Jun;184(6):987-989. doi: 10.1111/bjd.20050. PMID: 34091897
- 20 7. Simpson RC, Thomas KS, Murphy R. Outcome measures for vulval skin conditions: a systematic review
21 of randomized controlled trials. *Br J Dermatol*. 2013 Sep;169(3):494-501. doi: 10.1111/bjd.12391.
22 PMID: 23600623.
- 23 8. Goldstein AT, Marinoff SC, Christopher K, Srodon M. Prevalence of vulvar lichen sclerosis in a general
24 gynecology practice. *J Reprod Med*. 2005 Jul;50(7):477-80. PMID: 16130842.
- 25 9. Lansdorp CA, van den Hondel KE, Korfage IJ, et al. Quality of life in Dutch women with lichen
26 sclerosis. *Br J Dermatol*. 2013 Apr;168(4):787-93. doi: 10.1111/bjd.12137. Epub 2013 Mar 7. PMID:
27 23252667.
- 28 10. Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) Guideline on (anogenital) Lichen
29 sclerosis. *J Eur Acad Dermatol Venereol*. 2015 Oct;29(10):e1-43. doi: 10.1111/jdv.13136. Epub 2015
30 Jul 22. PMID: 26202852.
- 31 11. Halonen P, Jakobsson M, Heikinheimo O, et al. Lichen sclerosis and risk of cancer. *Int J Cancer*. 2017
32 May 1;140(9):1998-2002. doi: 10.1002/ijc.30621. Epub 2017 Feb 10. PMID: 28124469.
- 33 12. Bleeker MC, Visser PJ, Overbeek LI, et al. Lichen Sclerosis: Incidence and Risk of Vulvar Squamous Cell
34 Carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2016 Aug;25(8):1224-30. doi: 10.1158/1055-9965.EPI-
35 16-0019. Epub 2016 Jun 2. PMID: 27257093.
- 36 13. Sargeant HA, O'Callaghan FV. The impact of chronic vulval pain on quality of life and psychosocial
37 well-being. *Aust N Z J Obstet Gynaecol*. 2007 Jun;47(3):235-9. doi: 10.1111/j.1479-
38 828X.2007.00725.x. PMID: 17550493.
- 39 14. Sargeant HA, O'Callaghan F. Predictors of psychological well-being in a sample of women with vulval
40 pain. *J Reprod Med*. 2009 Feb;54(2):109-16. PMID: 19301573.
- 41 15. Arnold S, Fernando S, Rees S. Living with vulval lichen sclerosis: a qualitative interview study. *Br J*
42 *Dermatol*. 2022 Jul 13. doi: 10.1111/bjd.21777. Epub ahead of print. PMID: 35831927.
- 43 16. Chi CC, Kirtschig G, Baldo M, et al. Topical interventions for genital lichen sclerosis. *Cochrane*
44 *Database Syst Rev*. 2011(12):CD008240.
- 45 17. Simpson RC, Cooper SM, Kirtschig G, et al. Future research priorities for lichen sclerosis - results of a
46 James Lind Alliance Priority Setting Partnership. *Br J Dermatol*. 2019 May;180(5):1236-1237. doi:
47 10.1111/bjd.17447. Epub 2019 Jan 15. PMID: 30472735; PMCID: PMC6850137.

- 1 18. Kirkham JJ, Davis K, Altman DG, et al. Core Outcome Set-STAndards for Development: The COS-STAD
2 recommendations. PLoS Med. 2017 Nov 16;14(11):e1002447. doi: 10.1371/journal.pmed.1002447.
3 PMID: 29145404; PMCID: PMC5689835.
- 4 19. Schmitt J, Apfelbacher C, Spuls PI, et al. The Harmonizing Outcome Measures for Eczema (HOME)
5 roadmap: a methodological framework to develop core sets of outcome measurements in
6 dermatology. J Invest Dermatol. 2015 Jan;135(1):24-30. doi: 10.1038/jid.2014.320. Epub 2014 Sep 4.
7 PMID: 25186228.
- 8 20. The Core Outcomes for Research in Lichen Sclerosus (CORALS) initiative webpage:
9 <https://www.nottingham.ac.uk/research/groups/cebd/projects/5rareandother/corals.aspx>. Last
10 accessed 14/10/2022
- 11 21. Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the
12 management of lichen sclerosus, 2018. The British journal of dermatology. 2018;178(4):839-53.
- 13 22. Green N, Sheinis M, Selk A. Vulvar Lichen Sclerosus: Outcomes Important to Patients in Assessing
14 Disease Severity. J Low Genit Tract Dis. 2020 Jul;24(3):299-304. doi: 10.1097/LGT.0000000000000547.
15 PMID: 32569254.
- 16 23. Goodrum CA, Leighton PA, Simpson RC. Outcome domains in lichen sclerosus. Br J Dermatol. 2020
17 Nov;183(5):966-968. doi: 10.1111/bjd.19253. Epub 2020 Jul 27. PMID: 32471015.
- 18 24. Rees, Sophie, Kirby, L., Simpson, R. C. (2019) *Living with vulval lichen sclerosus: a systematic*
19 *review*. British Journal of Dermatology, 180 (6). pp. 1555-1556. doi:10.1111/bjd.17790
- 20 25. Dodd S, Clarke M, Becker L, et al. A taxonomy has been developed for outcomes in medical research
21 to help improve knowledge discovery. J Clin Epidemiol. 2018 Apr;96:84-92. doi:
22 10.1016/j.jclinepi.2017.12.020. Epub 2017 Dec 28. PMID: 29288712; PMCID: PMC5854263.
- 23 26. COMET Initiative DelphiManager brochure weblink. [https://www.comet-
25 initiative.org/delphimanager/docs/DelphiManagerBrochureV4.0.pdf](https://www.comet-
24 initiative.org/delphimanager/docs/DelphiManagerBrochureV4.0.pdf). Last accessed 14/10/2022
- 26 27. SurveyMonkey software webpage <https://www.surveymonkey.com>. Last accessed 14/10/2022
- 27 28. Eleftheriadou V, Thomas K, van Geel N, et al. Developing core outcome set for vitiligo clinical trials:
28 international e-Delphi consensus. Pigment Cell Melanoma Res. 2015 May;28(3):363-9. doi:
29 10.1111/pcmr.12354. Epub 2015 Feb 13. PMID: 25645179.
- 30 29. Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial
31 outcomes: an international Delphi process. Br J Dermatol. 2018 Sep;179(3):642-650. doi:
32 10.1111/bjd.16672. Epub 2018 Jul 5. PMID: 29654696; PMCID: PMC6141318.
- 33 30. Schmitt J, Langan S, Stamm T, Williams HC; Harmonizing Outcome Measurements in Eczema (HOME)
34 Delphi panel. Core outcome domains for controlled trials and clinical recordkeeping in eczema:
35 international multiperspective Delphi consensus process. J Invest Dermatol. 2011 Mar;131(3):623-30.
36 doi: 10.1038/jid.2010.303. Epub 2010 Oct 14. PMID: 20944653.
- 37 31. Lechner A, Coleman S, Balzer K, et al. Core outcomes for pressure ulcer prevention trials: results of an
38 international consensus study. Br J Dermatol. 2022 Jul 5. doi: 10.1111/bjd.21741. Epub ahead of print.
39 PMID: 35789479.
- 40 32. COMET document on 'Online consensus meetings for COS development – issues to consider' weblink:
41 [https://www.comet-
43 initiative.org/Downloads/Issues%20to%20consider%20for%20online%20consensus%20meetings.pdf](https://www.comet-
42 initiative.org/Downloads/Issues%20to%20consider%20for%20online%20consensus%20meetings.pdf).
44 Last accessed 14/10/2022
- 45 33. Schmitt J, Williams H; HOME Development Group. Harmonising Outcome Measures for Eczema
46 (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich,
Germany. Br J Dermatol. 2010 Dec;163(6):1166-8. doi: 10.1111/j.1365-2133.2010.10054.x. PMID:
21137114.

- 1 34. Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema
 2 research: results of the HOME II meeting. *Allergy*. 2012 Sep;67(9):1111-7. doi: 10.1111/j.1398-
 3 9995.2012.02874.x. Epub 2012 Jul 30. PMID: 22844983.
 4
- 5 35. Chalmers JR, Schmitt J, Apfelbacher C, et al.. Report from the third international consensus meeting
 6 to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). *Br J*
 7 *Dermatol*. 2014 Dec;171(6):1318-25. doi: 10.1111/bjd.13237. Epub 2014 Nov 14. PMID: 24980543;
 8 PMCID: PMC4298247.
- 9 36. Thorlacius L, Garg A, Ingram JR, et al. Towards global consensus on core outcomes for hidradenitis
 10 suppurativa research: an update from the HISTORIC consensus meetings I and II. *Br J Dermatol*. 2018
 11 Mar;178(3):715-721. doi: 10.1111/bjd.16093. Epub 2018 Feb 1. PMID: 29080368; PMCID:
 12 PMC5935265.
- 13 37. K S Thomas, C A Apfelbacher, J R Chalmers, et al. Recommended core outcome instruments for
 14 health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the
 15 HOME VII consensus meeting. *Br J Dermatol*. 2021 Jan 4. doi: 10.1111/bjd.19751
- 16 38. ACORN initiative [ACORN \(c3outcomes.org\)](https://www.acorn-c3outcomes.org) accessed 12/12/2022
- 17 39. Langbroek GB, Wolkerstorfer A, Horbach SER, Spuls PI, Kelly KM, Robertson SJ, van Raath MI, Al-
 18 Niaimi F, Kono T, Boixeda P, Laubach HJ, Badawi AM, Rubin AT, Haedersdal M, Manuskiatti W, van der
 19 Horst CMAM, Ubbink DT; COSCAM study group. A core outcome domain set for clinical research on
 20 capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting. *Br J*
 21 *Dermatol*. 2022 Nov;187(5):730-742. doi: 10.1111/bjd.21723. Epub 2022 Jul 31. PMID: 35762296.
- 22 40. Van den Bussche K, Kottner J, Beele H, De Meyer D, Dunk AM, Ersser S, Lange T, Petrovic M,
 23 Schoonhoven L, Smet S, Van Damme N, Verhaeghe S, Van Hecke A, Beeckman D. Core outcome
 24 domains in incontinence-associated dermatitis research. *J Adv Nurs*. 2018;74(7):1605-1617
 25
 26
 27

28 Supporting information

29
 30 Appendix S1:Facilitator pack for CORALS domain meeting
 31

32
 33 S2: COS-STAR reporting checklist
 34
 35
 36

37 Figure legends

38
 39 **Figure 1:** Electronic Delphi survey round 3- ranking results. Bars demonstrate the ranking for the 11
 40 outcome domains ('y' axis) that met consensus in by at least 1 stakeholder group in the first 2 Electronic
 41 Delphi rounds. The answer choice with the largest average ranking ('x' axis, 0=low; 9=high ranking))
 42 represents the most preferred choice.
 43

DOMAIN	EXPLANATION OF DOMAIN
Clinical (visible) signs	Examples include skin colour change, skin texture change, damage to surface of the skin, changes in the anatomy of the genital area
Control of disease	Includes length of time without flares, frequency of flares, progression of the disease
Development of vulval/penile cancer	Development of cancer
Extent of disease	Which parts of the genitals or anus are affected?
Histological changes	Changes seen when skin sample taken and specimen reviewed under the microscope by specialist doctor
Impact on important relationships	For example, relationships with partners, family relationships, interactions with friends, forming new relationships
Quality of life – general health	A more general measure looking at overall quality of life (i.e., someone's overall health and wellbeing both physical and psychological)
Quality of life-lichen sclerosis specific	Activities of daily living specific to genital lichen sclerosis
Sexual functioning	Including ability to enjoy closeness/tenderness, sexual desire or sexual interest, arousal during sexual activity or intercourse, ability to have an orgasm, satisfaction with sexual life and sexual relationships, pain/soreness (related to sexual activity), inability to tolerate or enjoy sex play or penetrative sex
Societal/resource use	Costs related to healthcare use and overall cost to society
Symptoms	Examples include itch, burning, irritation, pain/soreness (unrelated to sexual activity), feeling of dryness, fragile skin / splitting of skin (loss of elasticity of skin), bleeding, constipation, difficulty passing urine/pain when passing urine

1
2 **Table 1:** Long-list of LS outcome domains identified from review of literature (domains are presented in
3 alphabetical order)
4

Demographic	Delphi Round 1 N (%)	Delphi Round 2 N (%)	Delphi Round 3 N (%)	Consensus meetings 1+2 N (%)	Consensus meetings 3+4 N (%)
Total participants	199	141	123	42	29
Stakeholder group					
Health care professionals	71 (36)	54 (38)	44 (35)	21 (50)	14 (48)
Patients/patient representatives	126 (63)	85 (60)	77 (63)	15 (36)	9 (31)
Researchers	2 (1)	2 (1)	2 (2)	6 (14)	6 (21)
Minority group representation					
Representatives of children	41 (21)			19 (45)	10 (34)
Representatives of male patients	17 (9)			14 (33)	9 (22)
Geographical representation – country where participants came from					
Australia	9				1
Austria	2				
Brazil	2				
Canada	26			4	1
Chile	0			1	
Czech Republic	1				
Denmark	27			2	5
Germany	26			6	2
Finland	1				
France	2			1	1
Israel	3				
Italy	3			4	
Jersey	1				
Lithuania	1			1	1

Luxembourg	1			1	1
Mexico	1				
Netherlands	6			2	1
Northern Ireland	1				
New Zealand	3				1
Portugal	1				
Russia	1				
Scotland	1			1	1
Spain	1				
Switzerland	8				
Taiwan	1				
United Kingdom	35			11	8
USA	35			8	6

1 **Table 2:** Demographics of participants during 3 rounds of e-Delphi surveys and virtual consensus
 2 meetings
 3

1

Domain	Patients	Health care professionals/ researchers
Quality of life-lichen sclerosis specific	93%	96%
Control of disease	95%	89%
Symptoms	94%	88%
Development of vulval/penile cancer	84%	91%
Sexual functioning	84%	84%
Extent of disease	84%	77%
Emotional impact	86%	73%
Clinical (visible) signs	78%	75%
Quality of life – general health	84%	50%
Negative events of treatment	79%	61%
Treatment acceptability	71%	59%
Impact on important relationships	67%	68%
Histological changes	43%	32%
Societal/resource use	17%	10%

2 **Table 3:** Proportion of voters rating outcomes as 'critical' on 9-point Likert scale after 2 rounds of voting
3 in the e-Delphi surveys. **GREEN** = domain met consensus across all stakeholder groups as being critical,
4 **AMBER** = domain met consensus with one stakeholder group as being critical, **RED** = domain not voted as
5 critical by any stakeholder groups.
6

1
2

DOMAIN (Total number of voters for that domain)	Yes % (n)	No % (n)	Not sure % (n)	Didn't vote
Symptoms (n=39)	100 (39)	0	0	3
Quality of life-lichen sclerosis specific (n=39)	92 (36)	5 (2)	3 (1)	3
Control of disease (n=40)	65 (26)	15 (6)	20 (8)	2
Clinical (visible) signs (n=39)	64 (25)	18 (7)	18 (7)	3
Sexual functioning (n=39)	31 (12)	56 (22)	13 (5)	3
Extent of disease (n=39)	15 (6)	77 (30)	8 (3)	3
Treatment acceptability (n=39)	13 (5)	77 (30)	10 (4)	3
Negative effects of treatment (n=40)	10 (4)	75 (30)	15 (6)	2
Development of vulval/penile cancer (n=39)	8 (3)	74 (29)	18 (7)	3
Emotional impact (n=40)	8 (3)	75 (30)	17 (7)	2
Quality of life – general health (n=38)	5 (2)	95 (36)	0	4

3 **Table 4:** Results of virtual consensus meetings January 2022. Green = consensus met for domain to be in
4 the final core outcome set. Amber = consensus close and for further voting. White = consensus not met.

5
6

DOMAIN (Total number of voters for that domain)	Yes % (n)	No % (n)	Not sure % (n)	Didn't vote
Control of disease (n=29)	17 (5)	45 (13)	38 (11)	0
Clinical (visible) signs (n=29)	97(28)	0 (0)	3 (1)	0

7 **Table 5:** Results of virtual consensus meetings May/June 2022. Green = consensus met. White =
8 consensus not met.

9
10
11




Figure 1
166x101 mm (x DPI)

1
2
3

ACCEPTED MANUSCRIPT